Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 2/20 | 0.34 |
| ▸ | CCKBR | P32239 | 5/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018582 | 0.91 | PRCP (0.40) | TERTKEAP1BMP1GLO1MEN1 | |
| SCHEMBL29421961 | 0.90 | KEAP1 (0.44) | TERTKEAP1CALCRLMEN1KMT2A | |
| SCHEMBL29421977 | 0.88 | KEAP1 (0.44) | TERTKEAP1CALCRL | |
| SCHEMBL30930148 | 0.87 | MEN1 (0.41) | TERTKEAP1BMP1MEN1KMT2A | |
| SCHEMBL30930169 | 0.87 | MEN1 (0.41) | TERTKEAP1BMP1MEN1KMT2A | |
| SCHEMBL30824015 | 0.87 | NMT1 (0.44) | KEAP1 | |
| SCHEMBL29630716 | 0.86 | DPP7 (0.38) | TERTKEAP1BMP1GLO1MEN1 | |
| SCHEMBL29517049 | 0.86 | DPP7 (0.41) | TERTGLO1MEN1KMT2APRCP | |
| SCHEMBL29485647 | 0.86 | KEAP1 (0.43) | TERTKEAP1MEN1KMT2A | |
| SCHEMBL22922937 | 0.85 | KEAP1 (0.40) | TERTKEAP1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | EYEBIO KOREA (KR) | 2025-09-30 | — | — | US | disclosed |
| EP-4483959-A2 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-3974441-B1 | PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-10-24 | — | — | US | disclosed |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | VIP, FURIN, IAPP | TERT 3874/4885KEAP1 2728/4885CALCRL 423/4885 |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | TERT 4142/4885KEAP1 3089/4885CALCRL 456/4885 |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | TERT 4142/4885KEAP1 3089/4885CALCRL 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.